Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Jia Fan
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04649489CT.gov A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Venous Thromboembolism
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Atezolizumab (this asset) | Jia Fan | P3 | B · 60 |
| Warfarin | Northern Jiangsu People's Hospital | P4 | A |
| Apixaban | Regeneron Pharmaceuticals | P4 | BBB |
| Aspirin | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | P4 | BBB |
| Nadroparin | Rijnstate Hospital | P4 | BBB |
| Rivaroxaban | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | P3 | BBB |
| Dalteparin | Beijing Friendship Hospital | P4 | BBB |
| Dipyridamole | Northern Jiangsu People's Hospital | P4 | BB |
| Fondaparinux | University of Alabama at Birmingham | P2 | BB |
+20 more in the Venous Thromboembolism cohort
Other indications for Atezolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P2/3 | BB · 71 |
| Her2-Receptor Negative Breast Cancer | — | P2 | BB · 69 |
| Bladder Transitional Cell Carcinoma | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- WarfarinNorthern Jiangsu People's HospitalA
- ApixabanRegeneron PharmaceuticalsBBB
- AspirinUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyBBB
- NadroparinRijnstate HospitalBBB
- RivaroxabanUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyBBB
Citation
Floatz Terminal. Atezolizumab in Venous Thromboembolism. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/atezolizumab-venous-thromboembolism
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →